A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1/2 Recruiting
197 enrolled
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
Phase 1/2 Recruiting
40 enrolled
MK-3475-G21
Phase 1/2 Recruiting
20 enrolled
KEYNOTE-B98
Phase 1/2 Recruiting
110 enrolled
OrigAMI-4
Phase 1/2 Recruiting
287 enrolled
MK-3475-06C
Phase 1/2 Recruiting
160 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
MK-3475-04D
Phase 1/2 Recruiting
55 enrolled
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Phase 1/2 Recruiting
60 enrolled
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Phase 1/2 Recruiting
160 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Phase 1/2 Recruiting
193 enrolled
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
225 enrolled
FRAPPE
Phase 1/2 Recruiting
40 enrolled
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
361 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/2 Recruiting
428 enrolled
MK-3475-06E
Phase 1/2 Recruiting
298 enrolled
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Phase 1/2 Recruiting
41 enrolled
MK-5909-003
Phase 1/2 Recruiting
280 enrolled
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Phase 1/2 Recruiting
60 enrolled
MK-3475-06B
Phase 1/2 Recruiting
230 enrolled
KRAScendo 170
Phase 1/2 Recruiting
320 enrolled
SYNERGY-101
Phase 1/2 Recruiting
364 enrolled
aCCeleR8-001
Phase 1/2 Recruiting
282 enrolled
Keynote B59
Phase 1/2 Recruiting
317 enrolled
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
416 enrolled
MK-3475-051
Phase 1/2 Recruiting
370 enrolled
MK-3475-01A
Phase 1/2 Recruiting
450 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Phase 1/2 Recruiting
442 enrolled
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Phase 1/2 Recruiting
204 enrolled
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Phase 1/2 Recruiting
92 enrolled
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/2 Recruiting
616 enrolled
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1/2 Recruiting
220 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Phase 1/2 Recruiting
252 enrolled
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Phase 1/2 Recruiting
37 enrolled
MK-3475-D20
Phase 1/2 Recruiting
176 enrolled
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
Phase 1/2 Recruiting
47 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
KEYNOTE-365
Phase 1/2 Recruiting
1,200 enrolled
PREOPANC-5
Phase 1/2 Recruiting
66 enrolled
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
Phase 1/2 Recruiting
40 enrolled
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
Phase 1/2 Recruiting
436 enrolled
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Phase 1/2 Recruiting
66 enrolled
Study of Pembrolizumab and M032 (NSC 733972)
Phase 1/2 Recruiting
28 enrolled
MK-9999-02A
Phase 1/2 Recruiting
220 enrolled
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
Phase 1/2 Recruiting
135 enrolled